PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network Article

Full Text via DOI: 10.1161/JAHA.118.011246 PMID: 31020929 Web of Science: 000484574700021
Open Access

Cited authors

  • Chamberlain, Alanna M.; Gong, Yan; Shaw, Kathryn McAuliffe; Bian, Jiang; Song, Wen-Liang; Linton, MacRae F.; Fonseca, Vivian; Price-Haywood, Eboni; Guhl, Emily; King, Jordan B.; Shah, Rashmee U.; Puro, Jon; Shenkman, Elizabeth; Pawloski, Pamala A.; Margolis, Karen L.; Hernandez, Adrian F.; Cooper-DeHoff, Rhonda M.


  • Background-PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low-density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high-risk patients. We used real-world electronic health record data to characterize use of PCSK9 inhibitors, in addition to standard therapies, according to cardiovascular risk status.; Methods and Results-Data were obtained from 18 health systems with data marts within the National Patient-Centered Clinical Research Network (PCORnet) using a common data model. Participating sites identified >17.5 million adults, of whom 3.6 million met study criteria. Patients were categorized into 3 groups: (1) dyslipidemia, (2) untreated LDL >= 130 mg/dL, and (3) coronary artery disease or coronary heart disease. Demographics, comorbidities, estimated 10-year atherosclerotic cardiovascular disease risk, and lipid-lowering pharmacotherapies were summarized for each group. Participants' average age was 62 years, 50% were female, and 11% were black. LDL cholesterol ranged from 85 to 151 mg/dL. Among patients in groups 1 and 3, 54% received standard lipid-lowering therapies and a PCSK9 inhibitor was prescribed in <1%. PCSK9 inhibitor prescribing was greatest for patients with coronary artery disease or coronary heart disease and, although prescribing increased during the study period, overall PCSK9 inhibitor prescribing was low.; Conclusions-We successfully used electronic health record data from 18 PCORnet data marts to identify >3.6 million patients meeting criteria for 3 patient groups. Approximately half of patients had been prescribed lipid-lowering medication, but <1% were prescribed PCSK9 inhibitors. PCSK9 inhibitor prescribing increased over time for patients with coronary artery disease or coronary heart disease but not for those with dyslipidemia.

Publication date

  • 2019

International Standard Serial Number (ISSN)

  • 2047-9980


  • 8


  • 9